Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. [PDF]
OBJECTIVE: To identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd). METHODS: An analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 ...
Baljevic, Muhamed +8 more
core +1 more source
Immunotherapy advances for mesothelioma treatment. [PDF]
, 2017 INTRODUCTION Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ...
Ashtiani, Firozeh +5 more
core +4 more sources
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
ClinicoEconomics and Outcomes Research, 2020 Jan Bassali, 1 Ian Gopal Gould, 2 James A Kaye, 3 Deirdre Mladsi, 4 Jyotsna Mehta 5 1Global Medical and Scientific Affairs Department , Karyopharm Therapeutics, Newton, MA, 02459, USA; 2Research Health Economy, RTI Health Solutions, Research Triangle ...
Bassali J +4 more
doaj
Role of Bruton's tyrosine kinase in B cells and malignancies [PDF]
, 2018 Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Dammeijer, F. (Floris) +2 more
core +4 more sources
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study [PDF]
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed.
Bladé, Joan +20 more
core +3 more sources
Treatment of multiple myeloma with selinexor: a review
Therapeutic Advances in HematologyOver the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM.
Qianlei Huang +4 more
openaire +3 more sources
Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
CellsDespite the major advancements in the repertoire for multiple myeloma (MM) treatment, this disease remains a chronically progressive plasma cell malignancy. Drug resistance and high relapse rates complicate the extended treatment strategies. However, the tumor microenvironment (TME) in MM is decisive for the success of a therapy or relapse.
Tasbihi, Kereshmeh, Bruns, Heiko
openaire +4 more sources
Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1-mediated nuclear export [PDF]
, 2022 Angeli, Andrea +2 more
core +1 more source
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison [PDF]
Introduction: Matching adjusted indirect comparisons (MAICs) were performed to compare the efficacy of cilta-cel versus elotuzumab + pomalidomide + dexamethasone (EloPd), isatuximab + carfilzomib + dexamethasone ...
Burnett, Heather +24 more
core +1 more source
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia [PDF]
, 2017 C. J. Owen +5 more
core +1 more source